Back

WU 358: R10933-10987-COV-2066

Official Title

WU 358: A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19

Study Details

This research study is looking at an experimental drug for patients who are in the hospital because of COVID-19. The goals of the study include seeing whether the drug lowers infection by the virus, whether it reduces the need to be in the hospital or the need to have breathing support, and whether it can cause serious side effects.

Principal Investigator

Dr. Andrej Spec

IRB Number

202006063

NCT ID

NCT04425629

Eligibility

1. Participants must be 18 years of age or older
2. Participants must have a have tested positive for COVID-19 and require hospitalization

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back